314243-91-9

Upstream product

• 108-46-3 recorcinol 
• 1878-66-6 4-chlorophenylacetic Acid 
• 15485-64-0 2-(4-chlorophenyl)-1-(2,4-dihydroxyphenyl)ethan-1-one 
• 108-24-7 acetic anhydride 
• 140-53-4 p-chlorobenzyl cyanide 

Downstream Products

• 934710-78-8 3-(4-chlorophenyl)-7-hydroxy-2-methyl-4-oxo-4H-chromene-8-carbaldehyde 
• 98693-12-0 ethyl {[2-methyl-4-oxo-3-(4-chlorophenyl)-4H-chromen-7-yl]oxy}acetate 
• 1010903-54-4 1-({[2-methyl-4-oxo-3-(4-chlorophenyl)-4H-chromen-7-yl]oxy}acetyl)piperidine-3-carboxylic acid 
• 929417-54-9 {[2-methyl-4-oxo-3-(4-chlorophenyl)-4H-chromen-7-yl]oxy}acetic acid 
• 1007654-37-6 N-({[2-methyl-4-oxo-3-(4-chlorophenyl)-4H-chromen-7-yl]oxy}acetyl)glycine 

Relevant academic research and scientific papers

Synthesis of Isoflavone–Amino-Acid Conjugates

Conjugates of natural and synthetic amino acids and 7-hydroxyisoflavone in which the amino-acid residue was bonded to the isoflavone through a hydroxyacetate linker were prepared using the activated ester method.

CYTISINE-LINKED ISOFLAVONOID ANTINEOPLASTIC AGENTS FOR THE TREATMENT OF CANCER

Cytisine-linked isoflavonoids, or pharmaceutically acceptable salts thereof or pharmaceutically acceptable compositions thereof, are useful for the treatment of conditions in which cells have a reliance on peroxisomal HSD17B4 to degrade very long chain fatty acids and provide necessary energy for cell proliferation, such as is seen in colorectal cancer and prostate cancer, for example.

Developing antineoplastic agents that target peroxisomal enzymes: Cytisine-linked isoflavonoids as inhibitors of hydroxysteroid 17-beta-dehydrogenase-4 (HSD17B4)

Cytisine-linked isoflavonoids (CLIFs) inhibited PC-3 prostate and LS174T colon cancer cell proliferation by inhibiting a peroxisomal bifunctional enzyme. A pull-down assay using a biologically active, biotin-modified CLIF identified the target of these agents as the bifunctional peroxisomal enzyme, hydroxysteroid 17β-dehydrogenase-4 (HSD17B4). Additional studies with truncated versions of HSD17B4 established that CLIFs specifically bind the C-terminus of HSD17B4 and selectively inhibited the enoyl CoA hydratase but not the d-3-hydroxyacyl CoA dehydrogenase activity. HSD17B4 was overexpressed in prostate and colon cancer tissues, knocking down HSD17B4 inhibited cancer cell proliferation, suggesting that HSD17B4 is a potential biomarker and drug target and that CLIFs are potential probes or therapeutic agents for these cancers.

CHROMONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS

The present invention relates to the use of a chromone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form,